Analysis of complement pathway in dacryoadenitis of programmed cell death-1 deficient mice

被引：0
|
作者：
Sakurai, Yutaka [1 ]
Ito, Masataka [1 ]
Karasawa, Yoko [1 ]
Takeuchi, Masaru [1 ]
机构：
[1] Natl Def Med Collage, Tokoroawa, Saitama, Japan
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
4925
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice
    Ansari, MJI
    Salama, AD
    Chitnis, T
    Smith, RN
    Yagita, H
    Akiba, H
    Yamazaki, T
    Azuma, M
    Iwai, H
    Khoury, SJ
    Auchincloss, H
    Sayegh, MH
    JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01): : 63 - 69
  • [32] Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma
    Mantia, Charlene M.
    McDermott, David F.
    CANCER, 2019, 125 (23) : 4148 - 4157
  • [33] Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis
    Peled, Michael
    Strazza, Marianne
    Azoulay-Alfaguter, Inbar
    Mor, Adam
    INFLAMMATION, 2015, 38 (04) : 1573 - 1579
  • [34] The role of programmed death-1 pathway in a neutrophil mediated shock syndrome
    Zhu, B
    Raddassi, K
    Sayegh, MH
    Khoury, SJ
    CLINICAL IMMUNOLOGY, 2005, 115 : S155 - S155
  • [35] Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action
    Zhang, Ni
    Tu, Jingyao
    Wang, Xue
    Chu, Qian
    IMMUNOTHERAPY, 2019, 11 (05) : 429 - 441
  • [36] Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives
    Mann, Steven A.
    Lopez-Beltran, Antonio
    Massari, Francesco
    Pili, Roberto
    Fiorentino, Michelangelo
    Koch, Michael O.
    Kaimakliotis, Hristos Z.
    Wang, Lisha
    Scarpelli, Marina
    Ciccarese, Chiara
    Moch, Holger
    Montironi, Rodolfo
    Cheng, Liang
    CURRENT DRUG METABOLISM, 2017, 18 (08) : 700 - 711
  • [37] Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo
    Sandner, SE
    Clarkson, MR
    Salama, AD
    Sanchez-Fueyo, A
    Domenig, C
    Habicht, A
    Najafian, N
    Yagita, H
    Azuma, M
    Turka, LA
    Sayegh, MH
    JOURNAL OF IMMUNOLOGY, 2005, 174 (06): : 3408 - 3415
  • [38] Programmed death-1 blockade in mismatch repair deficient colorectal cancer.
    Le, Dung T.
    Uram, Jennifer N.
    Wang, Hao
    Bartlett, Bjarne
    Kemberling, Holly
    Eyring, Aleksandra
    Azad, Nilofer Saba
    Laheru, Dan
    Donehower, Ross C.
    Crocenzi, Todd S.
    Goldberg, Richard M.
    Fisher, George A.
    Lee, James J.
    Greten, Tim F.
    Koshiji, Minori
    Kang, SoonMo Peter
    Anders, Robert A.
    Eshleman, James R.
    Vogelstein, Bert
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege
    Cheng, Xuyang
    Dai, Hehua
    Wan, Ni
    Moore, Yolonda
    Vankayalapati, Ramakrishna
    Dai, Zhenhua
    TRANSPLANTATION, 2009, 87 (12) : 1778 - 1786
  • [40] Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights
    Schalper, Kurt A.
    Venur, Vyshak Alva
    Velcheti, Vamsidhar
    JOURNAL OF RECEPTOR LIGAND AND CHANNEL RESEARCH, 2015, 8 : 1 - 7
12345